Delergotrile (; developmental code name CM 29-712), also known as 6-methylergoline-8α-acetonitrile, is a dopamine receptor agonist of the ergoline family described as an antiparkinsonian agent which was never marketed. It is an analogue of lergotrile (LY-79907).
The drug shows high affinity for the dopamine D2 receptor (Ki = 34nM). In addition to dopamine receptors, delergotrile shows affinity for the serotonin 5-HT1 receptor (K0.5 = 2.0nM) and for the serotonin 5-HT2 receptor (Ki = 57nM), as well as for the α1- and α2-adrenergic receptors. The drug appears to be an agonist of both dopamine D1 and to a lesser extent D2 receptors. Due to its dopamine receptor agonism, delergotrile produces antiparkinsonian-like effects, induces changes in locomotor activity and stereotypy, and reverses reserpine-induced akinesia in rodents. It also produces effects consistent with weak blockade of α-adrenergic receptors in rodents.
Delergotrile was first described in the literature by 1976. It was developed by Sandoz.
See also Substituted ergoline
References